Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.